Andera Partners

Andera Partners, established in 2001, is a Paris-based private equity firm with a 250-year heritage tracing back to the Rothschild family. The firm manages over €2 billion, focusing on investments in unlisted companies across France and internationally. Andera Partners specializes in life sciences, growth capital, and sponsorless mezzanine debt, aiming to create long-term value for its investors.

Sirsa, established in 2014 and based in Paris, France, is a consulting firm focused on sustainable transformation. The company specializes in evaluating existing processes and analyzing risks to define strategies for transforming operations. Sirsa offers a comprehensive suite of services that includes implementing strategic plans, managing action plans, reporting results, and providing compliance services. The firm caters to a diverse range of industries, including aerospace, defense, food products, electrical equipment, healthcare, energy, medical supplies, environmental, and software sectors. In addition, Sirsa has developed a software-as-a-service (SAAS) platform that measures companies' extra-financial footprint and impacts, further enhancing its commitment to sustainability and operational effectiveness.

Bioclinic operates a network of medical analysis laboratories in the Ile-de-France region, serving health professionals, hospitals, clinics, care centers, and retirement homes. Founded in 1995 and based in Paris, the company specializes in areas such as molecular biology, genetics, antibiotic resistance, and reproductive health. By focusing on these fields, Bioclinic aims to provide clients and their patients with enhanced medical diagnostic results.

GLOBE Groupe sa is a Paris-based advertising agency that specializes in strategic marketing and communication services. The company focuses on shopper marketing to create impactful consumer experiences that drive sales. It offers a range of services including strategic planning, non-media planning, talent casting, recruitment, training, payroll, and logistics such as storage, dispatch, and cold-chain management. GLOBE Groupe also implements marketing activation campaigns and provides tools for performance measurement, utilizing key performance indicators to assess the effectiveness of its strategies. The firm caters to various sectors including consumer goods, media, retail, and recruitment, ensuring that its clients can adapt to the evolving landscape of consumer behavior and promotional messaging. Through its secure online platform, myGLOBE, clients can monitor operations in real-time, enhancing transparency and communication throughout the marketing process.

Allodiagnostic SAS is a company based in Paris, France, specializing in real estate diagnostics for private individuals during the rental or sale of properties. Established in 2001, it provides essential assessments, including termite inspections, electrical evaluations, and energy performance ratings. As the first expert network for mandatory real estate diagnostics in France, Allodiagnostic serves both individual clients and real estate professionals, offering tailored solutions to meet various diagnostic needs. The company has operated as a subsidiary of Edmond de Rothschild (France) since July 2017.

Finsecur S.A., established in 2000, is a French high-tech company specializing in the design, manufacturing, and maintenance of fire safety systems. Based in Paris, France, the company produces a range of products including fire detectors, control panels, accessories, alarm systems, extinguishant systems, and technical alarms for various industries such as clean rooms, agro-alimentary facilities, telecoms, airports, chemistry, military sectors, and warehouses. Finsecur was recognized with the BPI label Excellence, reflecting its innovative approach to fire safety solutions.

A2iA S.A. is a developer of advanced software solutions focused on handwritten and machine-printed text recognition, information extraction, and intelligent document classification. The company offers various toolkits, including a2ia Mobility, which supports multiple workflows for document processing; a2ia mNote, which digitizes handwritten notes directly on mobile devices; and a2ia DocumentReader, designed for data extraction from diverse document types. Additional products include a2ia TextReader for transcribing printed and cursive text, a2ia CheckReader for secure data capture from payment documents, and a2ia FieldReader for extracting information from forms. A2iA serves a wide range of industries, including banking, fintech, telecommunications, healthcare, insurance, and government, with a global presence across Europe, North America, Latin America, the Middle East, Africa, India, and the Asia Pacific. Founded in 1991 and headquartered in Paris, France, with an office in New York, A2iA operates as a subsidiary of Mitek Systems, Inc.

EOS Imaging SA is a medical technology company based in Paris, France, specializing in low-dose 2D/3D imaging and software solutions for osteo-articular conditions and orthopedic surgeries. The company develops and markets the EOS imaging system, which produces full-body, stereo-radiographic images of patients in functional positions, tailored to the specific needs of orthopedic surgeons and radiologists. Its product offerings include EOSedge, a high-quality X-ray system, sterEOS, a 3D modeling workstation for precise skeletal analysis, and EOSapps, online surgical planning solutions based on real-time imaging. Additionally, EOS Imaging creates planning software for knee and hip surgeries and manufactures patient-specific cutting guides for orthopedic procedures. The company operates globally, with a presence in Europe, the Middle East, Africa, North America, the Asia-Pacific, and Latin America, and has obtained marketing authorization for its systems in 48 countries. Founded in 1989, EOS Imaging was previously known as biospace med before rebranding in 2010.

Cellectis S.A. is a clinical-stage biotechnological company based in Paris, France, focused on developing innovative immuno-oncology therapies using gene-edited T-cells. The company specializes in allogeneic Chimeric Antigen Receptor T-cell (CAR-T) products, with a portfolio that includes several product candidates targeting various hematologic malignancies. Notable candidates include UCART19, aimed at treating CD19-expressing hematologic cancers such as acute lymphoblastic leukemia; UCART123 for acute myeloid leukemia; and UCARTCS1 and ALLO-715 for multiple myeloma. In addition to its therapeutic efforts, Cellectis also produces high oleic soybean oil and other soybean products, as well as fiber wheat. The company collaborates with various strategic partners, including Allogene Therapeutics and The University of Texas M.D. Anderson Cancer Center. Founded in 1999, Cellectis continues to advance its mission of eradicating cancer through cutting-edge gene-editing technologies.

Cellectis S.A. is a clinical-stage biotechnological company based in Paris, France, focused on developing innovative immuno-oncology therapies using gene-edited T-cells. The company specializes in allogeneic Chimeric Antigen Receptor T-cell (CAR-T) products, with a portfolio that includes several product candidates targeting various hematologic malignancies. Notable candidates include UCART19, aimed at treating CD19-expressing hematologic cancers such as acute lymphoblastic leukemia; UCART123 for acute myeloid leukemia; and UCARTCS1 and ALLO-715 for multiple myeloma. In addition to its therapeutic efforts, Cellectis also produces high oleic soybean oil and other soybean products, as well as fiber wheat. The company collaborates with various strategic partners, including Allogene Therapeutics and The University of Texas M.D. Anderson Cancer Center. Founded in 1999, Cellectis continues to advance its mission of eradicating cancer through cutting-edge gene-editing technologies.